norelgestromin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
steroids, progestogens 1959 53016-31-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • progestin norelgestromin
  • norelgestromin
  • 17-Deacetylnorgestimate
  • 18-Methylnorethindrone oxime
  • BRN 4202099
  • Levonorgestrel oxime
transdermal hormonal contraceptive
  • Molecular weight: 327.47
  • Formula: C21H29NO2
  • CLOGP: 3.92
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 52.82
  • ALOGS: -4.73
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.615 Moderate 0.76
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.493 Moderate 0.76
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 57.677 10^-6 cm/s Moderate 0.76
dh-clint Dog hepatocyte intrinsic clearance 20.749 uL/min/10^6 cells Moderate 0.76
dppb Dog plasma protein binding (% unbound) 2.920 % Moderate 0.76
fcs-ppb Fetal calf serum protein binding (% unbound) 4.850 % Moderate 0.76
herg hERG pIC50 4.999 pIC50 Moderate 0.76
hh-clint Human hepatocyte intrinsic clearance 6.324 uL/min/10^6 cells Moderate 0.76
hlm-clint Human liver microsomal intrinsic clearance 21.086 uL/min/mg protein Moderate 0.76
hppb Human plasma protein binding (% unbound) 2.500 % Moderate 0.76
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 30
kinase-selectivity-class AXL,EIF2AK3,GRK2,MAP2K6,MAP3K14,TGFBR1 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.627 Moderate 0.76
mh-clint Mouse hepatocyte intrinsic clearance 63.241 Moderate 0.76
mppb Mouse plasma protein binding (% unbound) 3.080 Moderate 0.76
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.841 Moderate 0.76
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 3.110 % Moderate 0.76
rh-clint Rat hepatocyte intrinsic clearance 75.336 uL/min/10^6 cells Moderate 0.76
rh-fuinc Rat hepatocyte fraction unbound in incubation 18.260 % Moderate 0.76
rppb Rat plasma protein binding (% unbound) 3.670 % Moderate 0.76
solubility-dd Solubility at pH 7.4 in DMSO 19.055 uM Moderate 0.76

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 2001 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03AA13 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
FDA CS M0447349 Progesterone Congeners
MeSH PA D000080066 Contraceptive Agents, Hormonal
MeSH PA D003270 Contraceptive Agents
MeSH PA D012102 Reproductive Control Agents
FDA EPC N0000175602 Progestin

Related Drugs by ATC class:

G03AA Progestogens and estrogens, fixed combinations 17 drugs
chlormadinonedesogestreldienogestdrospirenoneestetrolestradiolethinylestradioletynodiolgestodenelevonorgestrellynestrenolmedroxyprogesterone show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Contraception indication 13197004
Heart valve disorder contraindication 368009 DOID:4079
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Hypercholesterolemia contraindication 13644009
Jaundice contraindication 18165001
Myocardial infarction contraindication 22298006 DOID:5844
Diplopia contraindication 24982008
Retinal hemorrhage contraindication 28998008
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Chronic heart failure contraindication 48447003
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Deep venous thrombosis contraindication 128053003
Seizure disorder contraindication 128613002
Bed-ridden contraindication 160685001
Liver function tests abnormal contraindication 166603001
Mammography abnormal contraindication 168750009
Angina pectoris contraindication 194828000
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Endometrial carcinoma contraindication 254878006 DOID:2871
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Optic disc edema contraindication 423341008 DOID:146
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Diabetes with Vascular Disease Complication contraindication
Major Surgery with Prolonged Post-Operative Immobilization contraindication
Benign Hepatic Cell Adenoma contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.81 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Progesterone receptor Nuclear hormone receptor AGONIST WOMBAT-PK CHEMBL

External reference:

IDSource
4021295 VUID
N0000179766 NUI
D05205 KEGG_DRUG
4021295 VANDF
C1120952 UMLSCUI
CHEMBL1200807 ChEMBL_ID
DB06713 DRUGBANK_ID
C449219 MESH_SUPPLEMENTAL_RECORD_UI
62930 PUBCHEM_CID
7939 INN_ID
R0TAY3X631 UNII
326374 RXNORM
16209 MMSL
d04781 MMSL
009553 NDDF
385578004 SNOMEDCT_US
404867007 SNOMEDCT_US
CHEBI:135398 CHEBI
R0TAY3X631 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
XULANE HUMAN PRESCRIPTION DRUG LABEL 2 0378-3340 PATCH 150 ug TRANSDERMAL ANDA 28 sections
ZAFEMY HUMAN PRESCRIPTION DRUG LABEL 2 42291-930 PATCH 150 ug TRANSDERMAL ANDA 31 sections
XULANE HUMAN PRESCRIPTION DRUG LABEL 2 50090-1683 PATCH 150 ug TRANSDERMAL ANDA 28 sections
ZAFEMY HUMAN PRESCRIPTION DRUG LABEL 2 65162-358 PATCH 150 ug TRANSDERMAL ANDA 31 sections
Norelgestromin and Ethinly Estradiol HUMAN PRESCRIPTION DRUG LABEL 2 69238-1521 PATCH 150 ug TRANSDERMAL ANDA 31 sections
norelgestromin and ethinyl estradiol HUMAN PRESCRIPTION DRUG LABEL 2 70710-1190 PATCH 150 ug TRANSDERMAL ANDA 26 sections
norelgestromin and ethinyl estradiol HUMAN PRESCRIPTION DRUG LABEL 2 70771-1777 PATCH 150 ug TRANSDERMAL ANDA 1 sections
ZAFEMY HUMAN PRESCRIPTION DRUG LABEL 2 72162-2220 PATCH 150 ug TRANSDERMAL ANDA 31 sections